Myeloid leukemia chronic-phase

MeSH D015466 - myeloid leukemia chronic-phase

Favorite

Competitive Landscape

Events Timeline

Commercial

Clinical Trials

Competitive landscape

See list view

D015464:Bcr-abl positive chronic myelogenous leukemia

47 Companies

13 Drugs

Success rate

D015466:

Myeloid leukemia chronic-phase

2 Companies

1 Drug

Success rate

Events Timeline

Commercial

Company Name	Drug Name	Trade Name	Patent Expires	Approval Date	Revenue	Period
Novartis	Nilotinib	Tasigna	2023-07-04	2007-10-29	$1,977 M	Q2/20-Q2/23

Clinical Trials

Historical Success Rate

Phase 1

45%

41/91

Phase 2

27%

20/74

Phase 3

14%

3/22

Approved: 1Overall Success rate: 2%

All Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Company name

Phase 1

Phase 2

Phase 3

Phase 4

Drug Name

Novartis

Nilotinib,

Antithrombin iii